Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Practical Implications of No IGF-1 Elevation: The absence of IGF-1 stimulation makes AOD-9604 suitable for populations who need to avoid IGF-1 elevation, including individuals with personal or family history of hormone-sensitive cancers, those concerned about accelerated aging through growth pathway activation, people seeking fat loss without anabolic muscle-building effects, individuals who have contraindications to growth hormone therapy, and those undergoing screening or monitoring where IGF-1 elevation would be problematic
Injection : A small, quick injection is given in the muscle, typically in the upper arm or thigh
It is not supplied for human or veterinary use and must not be used for therapeutic, diagnostic, cosmetic, supplement, performance, weight-management, or personal-use purposes
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Many patients notice changes in energy, focus, and sleep within days rather than weeks
